Transfusion Requirements and Mortality during Extracorporeal Membrane Oxygenatio

Completed

Conditions: ECMO is indicated in case of potentially reversible cardio(respiratory) failure refractory to conventional therapies. It can be divided in two main groups: the respiratory indications (e.g. acute respiratory distress syndrome), for which veno-venous ECMO is indicated
and isolated cardiac or combined cardiorespiratory failure (e.g. acute myocardial infarction), for which veno-arterial ECMO is indicated. It is a vulnerable population in the ICU, for which ECMO often functions as a last resort” therapy.

Registration Number: NL-OMON24666

Lead Sponsor: /A

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Completed

Sex: Not specified

Target Recruitment: 600

Inclusion Criteria

Patients were included in the study if:
-They were admitted to the Intensive Care Unit (ICU) between January 1st 2018 up to July 1st 2019; AND
-They received support from extracorporeal membrane oxygenation (ECMO) during their ICU admission; AND
-They were aged 18 years and older.

Exclusion Criteria

Patients were excluded in the study if:
-The total duration of ECMO support was less than 24 hours.

Study & Design

Study Type: Observational non invasive

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The primary outcome is the total and daily amount of transfusion of blood products (red blood cells, platelets, plasma) and tranexamic acid, fibrinogen and prothrombin complex concentrate, received by patients on ECMO up to 28 days of support. Furthermore, clinical variables that may be associated with the occurrence of transfusion and a higher amount of transfusions will be evaluated.

Secondary Outcome Measures

Name	Time	Method
Secondary outcomes are the 28-day mortality (calculated as from ECMO initiation) and complication rate (hemorrhage, thrombosis, infection, acute kidney injury).